FierceBiotech 2026-01-08 Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M
FierceBiotech 2026-01-07 Pulmocide calls curtains on phase 3 antifungal trial over low response, higher mortality rate
FierceBiotech 2026-01-07 Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus’ replication
FierceBiotech 2026-01-07 Staar Surgical's takeover saga ends as shareholder revolt stops Alcon’s attempted merger deal
FierceBiotech 2026-01-07 Fierce Biotech Fundraising Tracker '26: Soley sees $200M series C; Rakuten rakes in $100M
FierceBiotech 2026-01-07 GSK's 'functional cure' for hep B proves worth in phase 3 trials setting up approval push
FierceBiotech 2026-01-06 Arrowhead takes aim at obesity market with early data on dual gene silencing assets
FierceBiotech 2026-01-06 Amgen stitches new acquisition worth up to $840M for UK biotech and its cancer programs
FierceBiotech 2026-01-06 Bright Minds shines with phase 2 win for anti-seizure serotonin receptor activator
FierceBiotech 2026-01-06 Boehringer continues kidney disease dealmaking run with $120M Variant Bio pact
FierceBiotech 2026-01-06 FDA cites severe liver injury risk, unclear benefit behind Sanofi's MS drug rejection
FierceBiotech 2026-01-06 UK biotech eyes $1B deal to enable eye gene therapy to be delivered in doctors' offices